Michelle L. Basil - 16 May 2025 Form 4/A - Amendment Insider Report for HAEMONETICS CORP (HAE)

Reporting relationship: EVP and General Counsel
Issuer ticker: HAE
Reported as of: 16 May 2025
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 13 Jun 2025, 16:26:00 UTC
Original report date: 20 May 2025
Prior SEC filing: 19 May 2025
Next SEC filing: 03 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Thomas V. Powers, attorney-in-fact for Ms. Basil

Key filing fact

Michelle L. Basil filed Form 4/A - Amendment for HAEMONETICS CORP (HAE) on 13 Jun 2025.

Key facts

This page summarizes Michelle L. Basil's Form 4/A - Amendment filing for HAEMONETICS CORP (HAE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 Jun 2025, 16:26.

Change

Previous filing in this sequence was filed on 19 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001699629 Primary reporting owner

Basil Michelle L

Relationship: EVP and General Counsel
Address: 125 SUMMER STREET, BOSTON
Signature: /s/ Thomas V. Powers, attorney-in-fact for Ms. Basil
Signature date: 13 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HAE transaction

Common Stock

Award

Transaction value
Shares: +6,755
Change %: +24%
Price
Shares after: 35,233
Date: 16 May 2025
Ownership: Direct
Footnotes: F1, F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HAE transaction Derivative

Non-qualified Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +14,626
Change %
Price: $0.000000
Shares after: 14,626
Date: 16 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,626
Exercise price: $70.31
Footnotes: F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

Footnote F2

On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of RSUs awarded to be 5,689 instead of 6,755. This net increase of 1,066 RSUs, and the corresponding change in securities beneficially owned by the reporting person, will be reflected in future filings by the reporting person.

Footnote F3

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Footnote F4

This number includes unvested RSUs previously reported.

Footnote F5

On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of options awarded to be 12,317 instead of 14,626. This net increase of 2,309 options will be reflected in future filings by the reporting person.

Footnote F6

Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.